Skip to Content
Søg Menu

Ph.d.: Real-world data for adjuverende behandling af T1abN0 brystkræft

I denne MEDtalk præsenterer Christina Marie Schiøttz Hassing, postdoc og læge, Afdeling for Brystkirurgi, Gentofte Hospital, resultater fra sin ph.d. baseret på DBCG-data. Afhandlingen belyser real-world data for adjuverende systemisk terapi hos patienter med T1abN0 brystkræft.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

LBA20: Sacituzumab govitecan significantly prolongs PFS versus chemotherapy in advanced triple-negative breast cancer

/ Jan Andreasen
ESMO25NBCNBrystcancer
John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
ESMO25NBCNBrystcancer Play the Video 03:24
Charles Geyer

ESMO 2025: Paradigm Shift in Breast Cancer Treatment

/ Charles E Geyer Jr.
ESMO25NBCNBrystcancer Play the Video 05:53

ESMO 2025: Treatment with CDK4/6 Inhibitors Extending Their Benefit and Reinforcing the Value for Patients with High-Risk HR+, HER2-Negative Early Breast Cancer

/ Jan Andreasen
ESMO25NBCNBrystcancer

ESMO 2025: A Potential New Anthracycline-Free Neoadjuvant Regimen for Patients with High-Risk HER2-Positive Early Breast Cancer

/ Jan Andreasen
ESMO25NBCNBrystcancer
Alan Celik

Palbociclib As First-Line Breast Cancer Treatment: A Danish Perspective

/ Alan Celik
NBCNBrystcancer Play the Video 06:19
Dimitrios Salgkamis

ESMO Breast Cancer 2025: Potential Biomarkers Linked to Hematologic Toxicity

/ Dimitrios Salgkamis
NBCNBrystcancer Play the Video 05:35
Kasper Kjærgaard

Postoperative komplikationer forringer overlevelse ved brystkræft men ikke tilbagefaldsrisikoen

/ Kasper Kjærgaard
NBCNType 2-diabetesBrystcancer Play the Video 03:07
Anders Winther Mølby Nielsen

New Data Support Boost in ER-/HER2- Breast Cancer

/ Anders W. Mølby Nielsen
NBCNBrystcancer Play the Video 08:40
Back to top